Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208046 | 0.78 | MAPT (0.41) | MAPTRAB9APOLB | |
| SCHEMBL17596553 | 0.78 | TSHR (0.55) | MAPTRAB9APOLB | |
| SCHEMBL30423225 | 0.78 | TSHR (0.55) | MAPTRAB9APOLB | |
| SCHEMBL30423048 | 0.78 | MAPT (0.41) | MAPTRAB9APOLB | |
| SCHEMBL18291356 | 0.78 | MAPT (0.41) | CHRNA7TAAR1MAPTRAB9APOLB | |
| SCHEMBL12763656 | 0.78 | MAPT (0.44) | MAPTRAB9APOLB | |
| SCHEMBL10265072 | 0.76 | MAPT (0.42) | HRH3PKMMAPTRAB9APOLB | |
| SCHEMBL10265053 | 0.75 | CHRNB2 (0.54) | HRH3KCNH2MAPT | |
| SCHEMBL5109117 | 0.74 | MAPT (0.44) | MAPTRAB9APOLB | |
| SCHEMBL30942630 | 0.74 | MAPT (0.44) | MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | CHRNA7 2277/4885HRH3 1937/4885PKM 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.